Introduction {#sec1}
============

Hypoxia is an oxygen-deprived condition of cells that is commonly observed in cancer and in neurodegenerative diseases like Alzheimer's and Parkinson's diseases.^[@ref1],[@ref2]^ In tumors, hypoxic cells are resistant to radiation recovery as oxygen is essential for fixation of radiation-induced damaged DNA. Identification of hypoxic cells plays a critical role for early diagnosis of disease conditions and hence the prevention of disease progression.

Various molecules have been studied as potential markers for detecting hypoxic cells, mostly radioactive molecules that are easy to follow using imaging techniques like positron imaging tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT).^[@ref3]^ One of the most common radiotracers for the detection of hypoxia is the nitroimidazole derivative ^18^F-fluromisonidazole (FMISO).^[@ref4],[@ref5]^ The mechanism of this radiotracer is based on the reduction of the nitrogen dioxide group to amine in low oxygen environments. The amine complex can then easily be trapped by proteins in the cellular environment, and the retention time of the tracer is increased in hypoxic tissues. However, because of their slow and passive uptake by cells, these tracers have not been used routinely. A waiting period of 1.5 h after injection is required to obtain a sufficient signal-to-background ratio approaching the half-life of ^18^F isotope; this delay results in an imaging time of a just few minutes.^[@ref6]−[@ref10]^

Owing to the potential of metal ions to undergo oxidation--reduction reactions, lately, researchers have been focused on metal-based radiotracers for high-sensitivity measurements of the cellular oxygen content. ^64^Cu(II) tracers,^[@ref11]^ such as ^64^Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) (ATSM-^64^Cu(II)), have been proposed as promising PET agents for hypoxia imaging (the copper binding structure is shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A).^[@ref12]−[@ref15]^ There are several advantages to ^64^Cu(II) isotope labeling: (1) the half-life (12.8 h) is not too long for patient exposure and enough time for handling the radio compound for imaging. (2) ATSM-^64^Cu(II) has demonstrated its ability to rapidly identify the hypoxic tissue owing to its small molecular weight and its high cell membrane permeability.^[@ref12],[@ref14],[@ref16]^ It was suggested that the ATSM-^64^Cu(II) tracer is actively taken up by the cell and is incorporated in the cellular copper cycle (shown in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B) by three proteins: Ctr1, Atox1, and ATP7B, and upon reduction at low oxygen levels (in hypoxic cells), Cu(I) is then sequestered from the ATSM ligand and further accumulates in the cells increasing its retention.^[@ref17]−[@ref20]^ Despite numerous studies on PET imaging applications of copper-based radiotracers, the mechanism of the cellular uptake of these radio-labeled copper complexes remains unclear, and indeed, no Cu(II)-based complexes have made through clinical trials for hypoxia imaging.

![(A) Structure of the ATSM-Cu(II) complex. (B) A proposed incorporation of the ATSM-Cu(II) complex into the cell through a cellular copper cycle involving Ctr1, Atox1, and ATP7B proteins. Nevertheless, the stability and the reactivity of the ATSM-Cu(II) complex in a cellular environment remain unclear. (C) Amino-terminal Cu(II)-binding (ATCUN) motifs found in (a) human serum albumin (HSA) protein and (b) extracellular N-terminal of human Ctr1 protein. (D) Human Atox1 Cu(I) metallochaperone (PDB 3IWX).](ao-2019-01748v_0001){#fig1}

We studied the interactions of ATSM-Cu(II) with human copper-binding peptides or protein under strong reducing conditions using UV--vis and electron paramagnetic resonance (EPR) spectroscopies. We used the extracellular peptides DAHK (ATCUN motif of HSA)^[@ref21]^ and NCtr1 (extracellular N-terminal of Ctr1 protein, also an ATCUN motif) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C) as competitive Cu(II) ligands against the ATSM ligand, as both of the peptides play a crucial role in the copper transport mechanism.^[@ref22]−[@ref25]^ This study suggests that ATSM-Cu(II) is highly stable and is not affected by the Cu(II)-binding peptides or by the reducing environment. The intracellular copper protein Atox1 (human) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}D) and glutathione (GSH) may affect the reduction of ATSM-Cu(II) through Cu(I) binding but both show low activity.

Experimental Section {#sec2}
====================

All chemicals obtained were of high-quality grade and used without further purification. 4-Methyl-3-thiosemicarbazide, diacetyl (2,3-butanedione), Cu(Cl)~2~·2H~2~O, bicinchoninic acid (BCA), [l]{.smallcaps}-ascorbic acid, glutathione, dithiothreitol (DTT), potassium dihydrogen phosphate (KH~2~PO~4~), and potassium hydrogen phosphate (K~2~HPO~4~) were purchased from Sigma-Aldrich. A rink amide resin was obtained from Applied Bio-System. *o*-(Benzotriazole-1-yl)-*N*,*N*,*N*′,*N*′-tetramethyluronium hexafluorophosphate (HBTU) was purchased from Dchem. N-α-Fmoc protected amino acids for peptide synthesis and coupling reagents were obtained from Novobiochem. Piperidine, *N*,*N*-dimethylformamide (DMF), 90% trifluoroacetic acid (TFA), and *N*,*N*-diisopropylethylamine (DIPEA) were obtained from Bio-Lab. Ethane dithiol (EDT), triisopropylsilane (TIS), bromotrimethylsilane (TMSBr), and thioanisole were purchased from Alfa Aesar, Haverhill, MA. Isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside was purchased from Calbiochem.

ATSM-Cu(II) Synthesis {#sec2.1}
---------------------

The ligand and complex were synthesized as previously reported.^[@ref26],[@ref27]^ATSM ligand: 4-Methyl-3-thiosemicarbazide (1.2 g, 11.4 mmol) was dissolved in ethanol (50 mL) with constant heating and stirring. Then, an ethanolic solution of diacetyl (2,3-butanedione) (0.5 mL, 5.7 mmol) was added dropwise in the solution. Further, the reaction mixture was added with 5--6 drops of glacial acetic acid. Then, the reaction mixture was refluxed at 60--70 °C for 4 h. A white-colored precipitate was formed. The flask was kept at 4 °C overnight for complete precipitation. On the next day, the pale, yellow precipitate of the ATSM ligand was obtained and then washed with ethanol and diethyl ether for 3--4 times each. ^1^H NMR (DMSO-*d*~6~): 10.22 (s, 2H) NH, 8.38 (m, 2H) NHCH~3~, 3.02 (d, 6H) NHCH~3~, 2.20 (s, 6H) 2xCH~3~. ESI-MS (+): *m*/*z* 260.4. ATSM-Cu(II) complex: The ATSM ligand (0.1 g, 0.38 mmol) was dissolved in ethanol. To this solution, the ethanolic solution of copper acetate (0.0768 g, 0.38 mmol) was added dropwise. The color of the solution changes from turbid white to brown red. The reaction mixture was refluxed at 60--70 °C for 3--4 h and then again refluxed overnight at room temperature. UV--vis spectroscopy: λ~max~ (DMSO) at 311 and 355 nm shoulder, 476 and 525 nm shoulder. ESI-MS (+): *m*/*z* 322.

Peptides {#sec2.2}
--------

The peptides DAHK-NH~2~ and MDHSHHMGMSYMDS-NH~2~ (NCtr1) were synthesized on a rink amide resin. All amino acids were protected with an Fmoc group (9-fluorenylmethoxycarbonyl). The coupling was achieved with HBTU in DMF in combination with *N*,*N*-diisopropylethylamine for a 1 h cycle. Fmoc deprotection was carried out with 30% piperidine in DMF. The cleavage of the peptide was achieved by treating the resin-bound peptides with a 5 mL cocktail of TFA, 5% EDT, 2.5% TIS, and 2.5% thioanisole for 2.5 h. An additional 65 μL of TMSBr was added during the last 30 min to minimize methionine oxidation in case of the NCtr1 peptide. The peptides were washed with cold diethyl ether, vortexed, and then centrifuged for 5 min at 3500 rpm. The same procedure was repeated four times. An amount of 10 mM DTT (in HPLC grade water) was added to the NCtr1 peptide. Peptides were further purified using preparative reversed-phase HPLC (Vydac, C18, 5 cm) and characterized using ESI-MS.

Stock Solutions Preparation {#sec2.3}
---------------------------

A stock solution of the ATSM ligand (10 mM) was prepared in DMSO.

Stock solutions of the peptides DAHK and NCtr1 were prepared by dissolving the powder into Milli-Q water. The concentration of the peptides was calibrated by Cu(II) titration in 0.1 M phosphate buffer(pH 7.4), which was monitored by UV--vis spectroscopy the formation of the d--d band for the 1:1 Cu(II)-peptide complex at 525 nm.^[@ref28]^ The concentration values of peptides were as follows: \[DAHK\] = 10 mM, \[NCtr1\] = 6 mM.

A stock solution of ascorbic acid (100 mM) was prepared freshly in Milli-Q water. A stock solution of GSH (100 mM) was prepared freshly in 0.1 N HCl. A stock solution of ATSM-Cu(II) (50 mM) was prepared in 100% DMSO and then further diluted to get the required concentration. A stock solution of Cu(II) (100 mM) was prepared in Milli-Q water and then further diluted for the different experiments. Its concentration was verified by UV--vis spectroscopy from the Cu(II) d--d band at 780 nm (ε = 12 M^--1^ cm^--1^). A stock solution of phosphate buffer (100 mM, pH 7.4) was prepared by mixing KH~2~PO~4~ in Milli-Q water and adjusted the pH value with a solution of NaOH. A stock solution of BCA (100 mM) was prepared in Milli-Q water.

Atox1 Cloning, Expression and Purification {#sec2.4}
------------------------------------------

The procedure of Atox1 expression and purification was described in detail earlier.^[@ref29],[@ref30]^ In general, the human pYTB12-Atox1 construct was kindly delivered to us by the lab of Prof. Lutsenko (Johns Hopkins University). The construct includes the Atox1 fusion protein with intein and chitin-binding domains. Initially transformation to the *Escherichia coli* strain BL21 (DE3) was performed. Cells were then grown to an optical density of 0.5--0.8 at 600 nm and induced with 1.0 mM isopropyl-β-[d]{.smallcaps}-thiogalactopyranoside for 18 h at 188 °C. Next, cells were harvested by centrifugation and suspended in lysis buffer (25 mM Na~2~HPO~4~, 150 mM NaCl, 20 μM PMSF, pH 7.5). Purification was done using a chitin bead column. The resin was washed with 30 column volumes of lysis buffer. For the cleavage, the beads were incubated in 50 mM DTT, 25 mM Na~2~HPO~4~, pH 8.9, and 150 mM NaCl for 40 h at room temperature. The eluted Atox1 was analyzed by SDS PAGE (tricine 19%).

The concentration of Atox1 protein (7500 Da, ε~280nm~ = 0.42 M) was determined from the absorbance at 280 nm using a NanoDrop 2000C spectrophotometer (Thermo Fischer Scientific).

UV--Visible Spectroscopy and Calculation of Dissociation Constant {#sec2.5}
-----------------------------------------------------------------

UV--vis measurements were performed using a Carry 5000 spectrometer at room temperature. Analyses were carried out in a high-precision cell with a 10 mm optical path length cell purchased from Hellma Analytics, except for Cu(II) titration in the ATSM ligand, 1 mM optical path length cell was used. Binding constants for ATSM, DAHK, and NCtr1 were calculated using a previously reported protocol.^[@ref31],[@ref32]^ Cu(II) titration in ligand solution was carried out using UV--vis spectroscopy. The titration of the ATSM ligand with Cu(II) was carried out in DMSO. The final concentration used for ligands was 0.5 mM, and aliquots of copper (3 μL) were subsequently added to get the desired concentration. The total volume of the solution was 300 μL. The titration of DAHK and NCtr1 was carried out in 30% DMSO in 0.1 M phosphate buffer (pH 7.4). The final concentration used for ligands was 0.5 mM, and aliquots of copper (1 μL) were subsequently added to get the desired concentration. The total volume of the solution was 100 μL. With the addition of Cu(II) aliquots, the d--d band appears indicating the formation of the Cu(II) complex.

The binding constant and stoichiometry for the complex of the interaction were obtained by fitting the observed absorbance data at 525 nm in cases of DAHK and NCtr1 peptides while at 475 nm for the ATSM ligand according to the following equationswhere *y* = \[Cu(II)\]/\[ligand\]; *x* = saturation fraction = *n*\[(ligand)*~n~*--Cu(II)\]/\[ligand\] = (*A* -- *A*~o~)/(*A*~¥~ -- *A*~o~), where *A*, *A*~o~, and *A*~¥~ are absorption values in the presence of Cu(II), in the absence of Cu(II), and at saturation of Cu(II), respectively. *C* is the total concentration of ligands, *n* is the copper-to-ligand binding stoichiometry ratio (herein, it is one), and *K* is the dissociation constant (Kd).

EPR Spectroscopy {#sec2.6}
----------------

CW-EPR spectra were recorded using an E500 Elexsys Bruker spectrometer operating at 9.0--9.5 GHz equipped with a super-high-sensitivity CW resonator. The spectra were recorded at low temperature (130 ± 5 K) at a microwave power of 20.0 mW, a modulation amplitude of 1.0 G, a time constant of 80 ms, and a receiver gain of 60.0 dB. The samples were measured in 4.0 mm quartz tubes (Wilmad-LabGlass, Vineland, NJ). CW-EPR simulations were carried out using MATLAB with the EasySpin toolbox.^[@ref33]^

Results and Discussion {#sec3}
======================

Copper is accumulated by the cell through the main copper transporter Ctr1 in a Cu(II) oxidation state. It was suggested that both the ATCUN motif in the N-terminal domain of Ctr1 and the His-rich motif were involved in Cu(II) acquisition from the blood carrier protein, human serum albumin (HSA).^[@ref23]−[@ref25]^ Cu(II) is then reduced to a Cu(I) state and directed by various metallochaperones to different cellular pathways: to the Golgi, superoxide dismutase, and mitochondria. One of these metallochaperones, Atox1, (also named Hah1)^[@ref34],[@ref35]^ is responsible for shuttling Cu(I) ions from Ctr1 to ATP7A/B in the Golgi. Here, we explore the binding of ATSM-Cu(II) to the ATCUN motif found in HSA, to the N-terminal domain of Ctr1 (NCtr1), and to the Atox1 metallochaperone.

Initially, we studied the effect of the Cu(II)-binding motifs, ATCUNs, on the stability of ATSM-Cu(II) complex. Peptides or proteins with the ATCUN motif have an N-terminal with a histidine residue at a third position, and these peptides or proteins show a high affinity toward Cu(II) and a dissociation constant reported to be in the range of 10^--12^ to 10^--15^ M at physiological conditions.^[@ref36]^ The ATSM-Cu(II) complex alone is stable under aerobic condition. The absorption spectrum of the ATSM-Cu(II) complex in dimethyl sulfoxide (DMSO) shows a characteristic signature in the absorption spectrum of the copper complex of bisthiosemicarbazones ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).^[@ref37]^ The ATSM ligand and ATSM-Cu(II) complex are insoluble in water and aqueous solutions. Therefore, to increase its solubility in the buffer (here, 0.1 M phosphate buffer, pH 7.4) and, at the same time, to match with physiological conditions, we used 30% DMSO in 0.1 M phosphate buffer as a solvent in most of our experiments. No significant changes in the pH value of the solution were observed before and after the reactions. The absorption spectrum of ATSM-Cu(II) in phosphate buffer showed a blue shift in the d--d band, that is, from 475 to 461 nm ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![UV--visible spectrum of 50 μM ATSM-Cu(II) in DMSO (gray) and 0.1 M phosphate buffer containing 30% DMSO (red).](ao-2019-01748v_0006){#fig2}

In the presence of Cu(II) chelators or reducing agents, a decrease in the intensity of the d--d band would be expected, indicating either the removal of Cu(II) from ATSM coordination or the reduction of Cu(II) to Cu(I). However, the addition of DAHK or NCtr1 peptides show no significant decrease in original d--d bands of ATSM-Cu(II) at least until 20 equivalent excess ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A). A small reduction in the absorption intensity at 461 nm was observed corresponding to the additive effect of the peptides. To gain more insight, we further calculated the dissociation constants for ATSM, DAHK, and NCtr1 to check their binding affinity for Cu(II). The spectrophotometric data fit well to the 1:1 ligand-to-metal binding isotherm ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)) with dissociation constants of DAHK and NCtr1 for copper binding in our experimental conditions were found to be 5.16 ± 1.4 × 10^--12^ and 7.42 ± 4.2 × 10^--9^ M, respectively, which are close to reported values.^[@ref36],[@ref38],[@ref39]^ The dissociation constant for the ATSM ligand was found to be 7.7 ± 2.02 × 10^--15^ M. Indeed, the ATSM ligand has more affinity to copper than ATCUN peptides. These data suggest that ATSM-Cu(II) remains stable in the presence of ATCUN motifs. Further, we carried out an X-band continuous wave (CW) EPR measurement at low temperatures (130 ± 5 K) to investigate the interactions of DAHK and NCtr1 peptides with the ATSM-Cu(II) complex. The ATSM-Cu(II) solution prepared in 0.1 M phosphate buffer was also calibrated against the Cu(II) solution in water ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)). The calibration showed that we succeeded in dissolving about 80% of the ATSM-Cu(II) in an aqueous environment of 0.1 M phosphate buffer (pH 7.4). The EPR spectra of ATSM-Cu(II) at phosphate buffer was simulated with *g* ∼2.0 and *A*~\|\|~ = 400 MHz indicating a type 1 Cu(II) spectra with a deviation from the square panel of 2N2S coordination.^[@ref40]^ No change in the EPR spectrum of the ATSM-Cu(II) complex was observed when 5 equiv of DAHK or NCtr1 was added with an overnight incubation with ATSM-Cu(II) in phosphate buffer ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B). The formation of DAHK-Cu(II) and NCtr1-Cu(II) complexes showed a distinct EPR signature of 2N2O/3N1O coordination ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)). Thus, UV--vis and EPR measurements confirmed that the ATSM-Cu(II) complex might remain intact in the extracellular environment and does not bind to proteins that are involved in the cellular copper cycle such as the ACTUN motif and NCtr1.

![(A) Change in the absorption of 50 μM ATSM-Cu(II) at 461 nm with the addition of 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 equiv of peptides, DAHK and NCtr1. The inset shows corresponding absorption spectra of the titration of 50 μM ATSM-Cu(II) with peptide. The UV--visible measurement was carried out in 0.1 M phosphate buffer (pH 7.4) with 30% DMSO. The concentration of titrating peptide used was 0.1 to 1 mM. (B) EPR measurements of ATSM-Cu(II) in the absence and the presence of 5 equiv of DAHK and NCtr1 peptides upon overnight incubation. EPR measurements were carried out in 0.1 M phosphate buffer (pH 7.4). The dashed line is a simulated spectrum.](ao-2019-01748v_0005){#fig3}

Next, we explored the effect of reductants on the ATSM-Cu(II) stability. Both the extracellular and intracellular environments contain a high concentration of reductants as a crucial part of the antioxidant network. One reductant, the intracellular ascorbate anion concentration may vary from 0.2 to 10 mM concentration.^[@ref41]^ GSH is a highly abundant tripeptide (0.5 mM--10 mM) known to reduce Cu(II) and bind Cu(I) via cysteine to assist intracellular Cu(I) transport.^[@ref42]−[@ref44]^ Additionally, the oxygen deprivation in hypoxic cells significantly adds to the reducing environment of those cells.

Wedd et al.^[@ref45]^ reported that the presence of 20 equiv of ascorbate or glutathione is not enough (even in anaerobic conditions) for the reduction of the ATSM-Cu(II) complex. Therefore, to determine the concentration of ascorbic acid (AA) required to reduce the ATSM-Cu(II) complex, we started with ascorbic acid and monitored the kinetics of the reduction of ATSM-Cu(II) with changing ascorbic acid concentrations ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A). There was no significant decrease in the absorption at 461 nm detected until 50 equiv of ascorbic acid. A small drop at 461 nm was seen with the addition of 75 equiv of ascorbic acid. The presence of oxygen perhaps efficiently oxidizes ATSM-Cu(I) to ATSM-Cu(II) against the slow reduction of ATSM-Cu(II). In the presence of 100 equiv (or more) of ascorbic acid, a significant decrease in the absorption intensity was observed, and the ATSM-Cu(II) complex was reduced entirely within 120 min ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A and [Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)). Salerno et al. also checked the stability of Cu(II)-bis(thiosemicarbazone) in the reducing environment of the cell and also refer to the Cu(II) complexes were highly stable.^[@ref46]^

![(A) Kinetics of the reduction of 50 μM ATSM-Cu(II) was monitored as a decrease in the absorption at 461 nm with increasing ascorbic acid (AA) concentration at an interval of 5 min for 110 min. (B) The kinetics of the reduction of 50 μM ATSM-Cu(II) was monitored at 461 nm after the addition of 5 mM AA, GSH, and [l]{.smallcaps}-Cysteine (100 equiv). All the reactions were carried out in 30% DMSO in 0.1 M phosphate buffer (pH 7.4).](ao-2019-01748v_0004){#fig4}

We also compared the ability of ascorbic acid to reduce the ATSM-Cu(II) complex with the biological reductants, [l]{.smallcaps}-cysteine (Cys) and GSH. We used 100 equiv of reductant in each case ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B, for full spectral traces, [Figures S6 and S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)). The rate of reduction of ATSM-Cu(II) in the presence of [l]{.smallcaps}-cysteine is higher than for GSH but lower than for ascorbic acid. However, the incomplete reduction is observed in a given condition. In the case of [l]{.smallcaps}-cysteine, a nearly 40% reduction was found in 50 min, ATSM-Cu(I) then reoxidized immediately to form the ATSM-Cu(II) complex. GSH slowly reduces ATSM-Cu(II). As GSH binds Cu(I), perhaps GSH forms a GSH-Cu(I) complex, however, the ATSM ligand may compete with Cu(I) binding, and the competition could favor an oxidation reaction to form ATSM-Cu(II). The reduction of Cu(II) complexes by using excess ascorbate could be used to screen for the Cu(II) complexes detecting hypoxic cells. Under our experimental conditions, the ability to reduce ATSM-Cu(II) by the reductants was found to be in the order of AA \> Cys \> GSH.

Further absorption measurements were carried out to confirm the reduction of ATSM-Cu(II) to either ATSM-Cu(I) or Cu(I). Initially, we used BCA as a Cu(I) indicator since the (BCA)~2~-Cu(I) complex has an absorption of the d--d band, and we can quantify it at 561 nm (ε = 7700 M^--1^ cm^--1^). The absorption spectrum of ATSM-Cu(II) with 5 equiv of BCA does not change for at least 60 min. With the addition of ascorbic acid at 100 equiv in the above solution, one would expect a complete reduction of Cu(II) to Cu(I) and the formation of 50 μM of the (BCA)~2~-Cu(I) complex. Interestingly, we observed two coexisting species, that is, ATSM-Cu(II) and (BCA)~2~-Cu(I) complexes, detected at 461 and 561 nm, respectively ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A). Similarly, the reduction of the ATSM-Cu(II) complex with the simultaneous (BCA)~2~-Cu(I) formation was studied in the presence of excess GSH. The absorption data showed that GSH at 100 equivalents reduces the ATSM-Cu(II) complex, but the rate is prolonged, which can be seen as a small elevation at 561 nm showing (BCA)~2~-Cu(I) formation ([Figures S8 and S9](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)). The reduction of ATSM-Cu(II) was facilitated in the presence of BCA; however, the ATSM ligand also competes with BCA for Cu(I) binding. ATSM-Cu(II) may interact with Cu(I) sinks like Atox1.

![(A) 50 μM ATSM-Cu(II) and 250 μM BCA with 5 mM ascorbic acid; (B) 50 μM ATSM-Cu(II) and 80 μM Atox1 with 5 mM ascorbic acid. The absorption measurement was carried out at an interval of 5 min. A concentration of 0.1 M phosphate buffer (pH 7.4) with 30% DMSO was used as a solvent. The inset shows the reduction of ATSM-Cu(II) at 461 nm and the formation of the (BCA)~2~-Cu(I) complex at 561 nm; an absorption at 561 nm was plotted after correction (subtracting the value at 700 nm), and here, the absorption value at 461 nm was plotted after correction (subtracting the value at 400 nm).](ao-2019-01748v_0003){#fig5}

To explore this possibility, the reduction of ATSM-Cu(II) with ascorbate was carried out in the presence of human Atox1 protein ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). The human Atox1 protein is reported to be a dimer consisted of two 68 amino acid monomers.^[@ref47]^ Atox1 binds Cu(I) with high affinity (Kd = 2 × 10^--14^ M) through the cysteine residues of the MXCXXC motif.^[@ref29],[@ref48]^ Wedd et al.^[@ref45]^ demonstrated that the nonphysiological reductant sodium dithionite at 20 equivalents immediately reduced ATSM-Cu(II) to ATSM-Cu(I), and then Cu(I) bound the proteins Atox1 and a cytosolic C-terminal domain of Ctr1 (Ctr1c, metallothionein-like) derived from the yeast *Saccharomyces cerevisiae,* but the reaction was prolonged. However, no reduction of ATSM-Cu(II) was observed in the presence of biological reducing agents, ascorbic acid (AA) and glutathione (GSH) at 20 equivalents.

We investigated, under our experimental conditions, whether the intracellular copper protein Atox1 retrieves Cu(I) from ATSM coordination and whether Atox1 affects the integration mechanism of ATSM-Cu(II). Interestingly, in the presence of Atox1, even the reduction of the ATSM-Cu(II) complex was inhibited ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B). We did not see the formation of the (BCA)~2~-Cu(I) complex from the ATSM-Cu(II) complex when the reaction was carried out in the presence of Atox1. This is perhaps due to interactions of Atox1 over BCA with Cu(I) ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}A and [Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf)). Similar results were obtained in the case of GSH as a Cu(I) chelator in the presence of excess ascorbic acid ([Figure S10](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b01748/suppl_file/ao9b01748_si_001.pdf), ESI). However, a low amount of (BCA)~2~-Cu(I) was identified, which confirms that GSH has lower affinity to bind Cu(I) than Atox1.

![(A) UV--visible spectra show the effect of Atox1 protein on the formation of the (BCA)~2~-Cu(I) complex. The samples were prepared in 0.1 M phosphate buffer (pH 7.4). (B) EPR spectra of copper in the absence and the presence of Atox1. The samples were prepared in 0.1 M phosphate buffer (pH 7.4). The samples were mixed well and incubated at 4 °C for 1 h before spectral measurements. (C) EPR spectrum of the ATSM-Cu(II) complex in the absence and presence of Atox1.](ao-2019-01748v_0002){#fig6}

We also carried out EPR measurements to check whether Atox1 interacted with ATSM-Cu(II), an interaction which might interfere with the reaction with ascorbic acid. Initially, we checked whether Cu(II) can coordinate with Atox1. The EPR spectra of free Cu(II) in the buffer and in the presence of Atox1 were identical ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}B), suggesting that Cu(II) cannot coordinate with Atox1. Indeed, the simulations showed 4O coordination of Cu(II) (*g*~\|\|~ = 2.38, *A*~\|\|~ = 420 MHz) confirming that Cu(II) was dissolved in water and not coordinated with Atox1. EPR spectra of ATSM-Cu(II) in the presence of Atox1 ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}C) showed no change, therefore also suggesting that ATSM-Cu(II) does not interact with Atox1 protein.

Conclusions {#sec4}
===========

Herein, we explored the binding of ATSM-Cu(II) to copper cellular proteins and their stability under reducing environments using spectrophotometric and EPR measurements. We showed that ATSM-Cu(II) remains intact against the extracellular high-affinity Cu(II) binding motifs, DAHK and NCtr1. This study proposes that ATSM-Cu(II) does not bind to proteins that are involved in the copper cycle. It is important to note that these experiments were performed in vitro, and in the cell other cellular pathways may assist in shuttling ATSM-Cu(II). Cell experiments should be performed to verify weather ATSM-Cu(II) is only passively taken by the cell, or there are other pathways behind the cellular copper carriers that may assist in actively transfer it to the cell.

Then, we checked the stability of ATSM-Cu(II) in a reducing environment. We showed that only high concentration of reductant in the order of the 100-fold excess of the physiological reductants ascorbate, [l]{.smallcaps}-Cys, and GSH can reduce the ATSM-Cu(II) complex incompletely, in the order of AA \> [l]{.smallcaps}-Cys \> GSH (when the reaction is open to air). This indicates that ATSM-Cu(II) is highly stable, and therefore, it will be able to be reduced only in severe hypoxic conditions. Moreover, probably its reducing time will take several hours, which limits its applications as a biomarker for hypoxia.

Interestingly, we found out that the presence of Cu(I) cellular protein, such as Atox1, significantly decreases the rate of ATSM-Cu(II) reduction. Altogether, the results presented here propose the poor efficiency of ATSM-Cu(II) as a biomarker for hypoxia. Since this complex cannot bind to proteins that are involved in the copper cycle, its reduction efficiency is low, and proteins in the cell can decrease the reduction rate even more.
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AA

:   L- ascorbic acid

GSH

:   glutathione

Cys

:   L-cysteine

NCtr1

:   extracellular N-terminal of Ctr1 protein (1--14)

EPR

:   electron paramagnetic resonance
